Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Ribobay Builds Shanghai Oligonucleotide Plant using Cytiva’s FlexFactory

publication date: May 10, 2024

Shanghai Ribobay Pharma has built a cGMP-level oligonucleotide manufacturing center using Cytiva's first FlexFactory platform for oligo manufacturing. Ribobay, a spin-off of General Biol (Anhui), said the facility will be ready to start manufacturing oligo in June, with the ability to produce several hundred kilograms of pharmaceutical oligo per year. Cytiva, headquartered near Boston, is a division of Danaher. Cytiva’s FlexFactory offers one-stop integrated services, from factory design to equipment and technologies that enable cGMP manufacturing. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital